Transcriptomic "portraits" of canine mammary cancer cell lines with various phenotypes.
In light of the high incidence of mammary cancer in dogs and completion of the canine genome sequencing, the new possibilities of gene profiling by using DNA microarrays give hope to veterinary oncology. The cell lines isolated from mammary tumors are a valuable tool in developing and testing new pathway-specific cancer therapeutics. Differential cytometric analysis of 6 canine mammary cancer cell lines was performed. We divided cell lines into 3 groups based on their phenotype: 2 lines with high proliferative potential, 2 lines with high antiapoptotic potential, and 2 lines with high metastatic potential. DNA microarray analysis revealed common genes for cell lines of each group. We found that genes encoding the receptors for growth hormone and ghrelin are related to high proliferation rate, while ABR (active BCR-related) and TMD1 (TM2 domain containing 1) genes are related to a high antiapoptotic potential of the cancer cells. Metastatic properties of mammary cancer cells seem to be associated with elevated expression of PGP (P glycoprotein), SEMA3B (semaphorin 3B), and STIM1 (stromal interaction molecule 1).
Król
M
M
Department of Physiological Sciences, Faculty of Veterinary Medicine, Warsaw University of Life Sciences (SGGW), Warsaw, Poland.
Pawłowski
K M
KM
Skierski
J
J
Turowski
P
P
Majewska
A
A
Polańska
J
J
Ugorski
M
M
Morty
R E
RE
Motyl
T
T
D000230:Adenocarcinoma / Q000235:genetics / Q000473:pathology / Q000662:veterinary; D000818:Animals; D002455:Cell Division; D045744:Cell Line, Tumor; D004273:DNA, Neoplasm / Q000235:genetics; D004283:Dog Diseases / Q000235:genetics*; D004285:Dogs; D005260:Female; D020869:Gene Expression Profiling; D007700:Kinetics; D015674:Mammary Neoplasms, Animal / Q000235:genetics* / Q000473:pathology; D020411:Oligonucleotide Array Sequence Analysis; D010641:Phenotype; D011003:Ploidies
D004273:DNA, Neoplasm
Cancer Res. 2005 Jul 15;65(14):6167-77
16024618
Anim Genet. 2008 Aug;39(4):333-45
18462483
Future Oncol. 2006 Feb;2(1):91-100
16556076
Proc Natl Acad Sci U S A. 2005 Mar 22;102(12):4252-7
15755808
In Vitro Cell Dev Biol. 1992 May;28A(5):309-19
1375928
Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8
9843981
Leukemia. 2001 Dec;15(12):1823-33
11753601
Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21
11309499
Anal Biochem. 2006 Sep 1;356(1):36-43
16844072
J Physiol Pharmacol. 2009 May;60 Suppl 1:73-84
19609016
Breast Cancer Res Treat. 2000 Jun;61(3):197-210
10965996
Vet Pathol. 2006 Nov;43(6):934-42
17099150
Nat Genet. 2003 Jan;33(1):49-54
12469122
CA Cancer J Clin. 2002 Jan-Feb;52(1):50-9
11814065
Nature. 2002 Jan 31;415(6871):530-6
11823860
Nucleic Acids Res. 2002 Nov 1;30(21):e116
12409475
J Exp Med. 2008 May 12;205(5):1155-71
18458115
Cancer Res. 1988 Jun 15;48(12):3411-7
3370639
Pol J Vet Sci. 2002;5(1):1-5
11944580
Nature. 2005 Dec 8;438(7069):803-19
16341006
Mol Cancer. 2006 Sep 05;5:34
16953886
Endocr Relat Cancer. 2005 Dec;12(4):839-50
16322325
Nucleic Acids Res. 2005 Jan 1;33(Database issue):D284-8
15608197
J Biol Chem. 2004 Sep 10;279(37):38083-6
15247279
Biostatistics. 2003 Jul;4(3):465-77
12925512
Genome Biol. 2007;8(1):R2
17204140
Genes Dev. 2004 Nov 1;18(21):2581-95
15520278
J Appl Genet. 2010;51(1):37-50
20145299
J Physiol Pharmacol. 2009 May;60 Suppl 1:85-94
19609017
Am J Pathol. 2001 Apr;158(4):1217-22
11290538
J Clin Pharmacol. 2005 Aug;45(8):872-7
16027397
J Physiol Pharmacol. 2009 May;60 Suppl 1:95-106
19609018
Carcinogenesis. 2006 Sep;27(9):1867-75
16606630